Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 1.00 |
| ▸ | HTR2A | P28223 | 14/20 | 1.00 |
| ▸ | HTR2B | P41595 | 13/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL174576 | 0.98 | HTR2C (0.96) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Hydrochloric Acid SCHEMBL174589 | 0.98 | HTR2C (0.96) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Iodide SCHEMBL174548 | 0.98 | HTR2C (0.96) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Water SCHEMBL16465743 | 0.98 | HTR2C (0.96) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Hydrochloric Acid SCHEMBL175004 | 0.96 | HTR2C (0.93) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Hydrochloric Acid SCHEMBL175003 | 0.96 | HTR2C (0.93) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Phosphoric Acid SCHEMBL174885 | 0.90 | HTR2C (0.81) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Sulfuric Acid SCHEMBL174315 | 0.90 | HTR2C (0.81) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Fumaric Acid SCHEMBL175130 | 0.86 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A | |
| Glycolic Acid SCHEMBL173573 | 0.86 | HTR2C (0.74) | HTR2CHTR2AHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-26 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-114948963-A | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-08-30 | — | — | CN | disclosed |
| CN-108617166-B | Protein kinase inhibitor benzolactam compounds | 大冢制药株式会社 | 2022-05-17 | — | — | CN | disclosed |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-06-21 | — | — | US | disclosed |
| WO-2005042491-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005042490-A1 | BENZAZEPINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| EP-1411881-A4 | 5HT sb 2C /sb RECEPTOR MODULATORS | ARENA PHARM INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1411881-A2 | 5HT sb 2C /sb RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003086306-A2 | 5HT2C RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-0628030-A1 | 2,3,4,5-TETRAHYDRO-1H --3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF $g(a)-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORPORATION (US) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016997-A1 | 2,3,4,5-TETRAHYDRO-1H^_-3-BENZAZEPINES HAVING ANTI-PSYCHOTIC ACTIVITY, AND SYNTHESIS OF α-SUBSTITUTED-ARYLACETAMIDES | SCHERING CORPORATION (US) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11939321-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HTR2C 2712/4885HTR2A 3716/4885HTR2B 3566/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTR2C 2712/4885HTR2A 3716/4885HTR2B 3566/4885 |
| US-20080009478-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2c Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | HTR2C 1/4885HTR2A 2/4885HTR2B 3/4885 |
| US-20070275949-A1 | Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases | HTR2C, HTR2A, HTR2B | HTR2C 1/4885HTR2A 2/4885HTR2B 3/4885 |
| US-20240368136-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTR2C 2742/4885HTR2A 3719/4885HTR2B 3587/4885 |
| US-20070142357-A1 | Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, TPH2, HTR2A | HTR2C 1/4885HTR2A 3/4885HTR2B 4/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | HTR2C 1020/4885HTR2A 754/4885HTR2B 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.